Hepatitis A and B immunization for individuals with inherited bleeding disorders

Haemophilia

Volumn 15, Issue 2, 2009, Pages 437-447

  Steele, MacGregor ^a,b   Cochrane, A ^a   Wakefield, C ^a   Stain, A M ^a   Ling, S ^a   Blanchette, V ^a   Gold, R ^a   Ford Jones, L ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Bleeding disorders; Guidelines; Hemophilia; Hepatitis A; Hepatitis B; Immunization; Vaccination

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADVISORY COMMITTEE; BLEEDING DISORDER; DOSE TIME EFFECT RELATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HEMOPHILIA; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INJECTION SITE CONTUSION; INJECTION SITE REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROLOGY;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMOPHILIA A; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; YOUNG ADULT;

EID: 63349109590     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01954.x     Document Type: Review

References (64)

1. Goedert JJ, Brown DL, Hoots K, Sherman KE. Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 2004; 10(Suppl 4): 205-10.
2. Burrell CJ, Black SH, Ramsay DM. Antibody to hepatitis B surface antigen in haemophiliacs on long-term therapy with Scottish factor VIII. J Clin Pathol 1978; 31: 309-12.
3. Craske J, Kirk P, Cohen B, Vandervelde EM. Commercial factor VIII associated hepatitis, 1974-75, in the United Kingdom: A retrospective survey. J Hyg 1978; 80: 327-36.
4. Holsteen V, Skinhoj P, Cohn J. Hepatitis, type B in haemophiliacs. Relation to the source of clotting factor concentrates. Scand J Haematol 1977; 18: 214-8.
5. Brackmann HH, Oldenburg J, Eis-Hubinger AM, Gerritzen A, Hammerstein U, Hanfland P. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center. Vox Sang 1994; 67(Suppl 1): 3-7; discussion 8.
6. Johnson Z, Thornton L, Tobin A et al. An outbreak of hepatitis A among Irish haemophiliacs. Int J Epidemiol 1995; 24: 821-8.
7. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-9.
8. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 2000; 18(Suppl 1): S71-4.
9. Juszczyk J. Clinical course and consequences of hepatitis B infection. Vaccine 2000; 18(Suppl 1): S23-5.
10. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977; 105: 94-8.
11. McMahon BJ, Alward WL, Hall DB et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603.
12. Van Damme P, Tormans G, Beutels P, Van Doorslaer E. Hepatitis B prevention in Europe: A preliminary economic evaluation. Vaccine 1995; 13(Suppl 1): S54-7.
13. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
14. Goedert JJ, Eyster ME, Lederman MM et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100: 1584-9.
15. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17: 120-62.
16. Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23: 392-403.
17. Demicheli V, Tiberti D. The effectiveness and safety of hepatitis A vaccine: A systematic review. Vaccine 2003; 21: 2242-5.
18. Advisory Committee on Immunization Practices. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40: 1-25.
19. Centers for Disease Control and Prevention. Hepatitis A; hepatitis B. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th edn. Washington DC: Public Health Foundation, 2008: 197-234.
20. National Advisory Committee on Immunization. Canadian Immunization Guide. Ottawa,Ontario, Canada: Public Health Agency of Canada, 2006.
21. Salisbury D, Ramsay M, Noakes K (eds). Immunisation against Infectious Disease. London: Department of Health, 2006.
22. Medical and Scientific Advisory Council, National Hemophilia Foundation. MASAC recommendations for hepatitis A and B immunization of individuals with bleeding disorders (2001). Available at: http://www.hemophilia.org/ NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=240 (last accessed on 1 April 2006).
23. Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Available at: http://www.ahcdc.ca/vwdcare.html (last accessed on 1 April 2006).
24. Makris M, Baglin T, Dusheiko G et al. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001; 7, 339-45.
25. World Federation of Hemophilia. Guidelines for the management of hemophilia. Available at: http://www.wfh.org/index.asp?lang=EN (last accessed on April 2006).
26. Wahl M, Hermodsson S. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: Side effects and antibody response. Scand J Infect Dis 1987; 19: 617-21.
27. Hedner U, Hansson BG, Vermylen J, Verstraete M, Colaert J, Desmyter J. Immunization of haemophiliacs against hepatitis B. A joint study between the haemophilia centers in Leuven, Belgium and Malmo, Sweden. Scand J Haematol Suppl 1984; 40: 317-21.
28. Janco RL. Immunogenicity of subcutaneous hepatitis B vaccine in hemophiliacs. J Pediatr 1985; 107: 316.
29. Maris JM, Butler RB, Cohen AR. Loss of detectable antibody to hepatitis B surface antigen in immunized patients with hemophilia but without human immunodeficiency virus infection. J Pediatr 1995; 126: 269-71.
30. Santagostino E, Mannucci PM, Gringeri A et al. Accelerated schedule of hepatitis B vaccination in patients with hemophilia. J Med Virol 1993; 41: 95-8.
31. Zanetti AR, Mannucci PM, Tanzi E et al. Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti-LAV/HTLV-III-positive patients. Am J Hematol 1986; 23: 339-45.
32. Miller EJ, Lee CA, Karayiannis P, Holmes S, Thomas HC, Kernoff PB. Immune response of patients with congenital coagulation disorders to hepatitis B vaccine: Suboptimal response and human immunodeficiency virus infection. J Med Virol 1989; 28: 96-100.
33. Pillay D, Pereira C, Sabin C, Powell L, Zuckerman AJ, Lee CA. A long-term follow-up of hepatitis B vaccination in patients with congenital clotting disorders. Vaccine 1994; 12: 978-83.
34. Chan W, Petric M, Wang E, Koren G, Read S, Blanchette V. Response to hepatitis B immunization in children with hemophilia: Relationship to infection with human immunodeficiency virus type 1. J Pediatr 1990; 117: 427-30.
35. Kavakli K, Nisli G, Cetingul N, Oztop S, Bilgic A, Ozacar T. Hepatitis B vaccination in children with thalassemia, hemophilia and cancer. Pediatr Infect Dis J 1996; 15: 1140-1.
36. Evans DI, Shaw A. Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. BMJ 1990; 300: 1694-5.
37. Makris M, Conlon CP, Watson HG. Immunization of patients with bleeding disorders. Haemophilia 2003; 9: 541-6.
38. Mast EE, Margolis HS, Fiore AE et al., P. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: Immunization of infants, children, and adolescents. [erratum appears in MMWR Morb Mortal Wkly Rep. 2006 Feb 17;55(6):158-9]. MMWR Recomm Rep 2005; 54, 1-31.
39. Banatvala J. Are booster immunisations needed for lifelong hepatitis B immunity? The Lancet 2000; 355: 561-5.
40. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccine 1996; 14: 1019-27.
41. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis 1998; 26: 933-7.
42. Zanetti AR, Mariano A, Romano L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: An Italian multicentre study. Lancet 2005; 366: 1379-84.
43. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007; 5: 79-84.
44. Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, Lafaix C. Immunogenicity and safety of a new inactivated hepatitis A vaccine: A clinical trial with comparison of administration route. Vaccine 1996; 14: 1132-6.
45. Linglof T, van Hattum J, Kaplan KM et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity. Vaccine 2001; 19: 3968-71.
46. Pancharoen C, Mekmullica J, Thisyakorn U, Kasempimolporn S, Wilde H, Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin Infect Dis 2005; 41: 1537-40.
47. Ragni MV, Lusher JM, Koerper MA, Manco-Johnson M, Krause DS. Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. Haemophilia 2000; 6: 98-103.
48. Santagostino E, Gringeri A, Rocino A, Zanetti A, de Biasi R, Mannucci PM. Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994; 72: 508-10.
49. Tilzey AJ, Palmer SJ, Harrington C, O'Doherty MJ. Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996; 14: 1039-41.
50. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-34.
51. Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327: 453-7.
52. National Advisory Committee on Immunization. Canadian Immunization Guide. Ontario: Canadian Medical Association, 2002.
53. Van Damme P, Banatvala J, Fay O et al. Hepatitis A booster vaccination: is there a need? The Lancet 2003; 362: 1065-71.
54. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12years after the primary course. J Med Virol 2004; 72: 194-6.
55. Werzberger A, Mensch B, Nalin DR, Kuter BJ. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9years' followup after the Monroe field trial of VAQTA. Vaccine 2002; 20: 1699-701.
56. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 2002; 68: 489-93.
57. Wiens BL, Bohidar NR, Pigeon JG et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996; 49: 235-41.
58. Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-6.
59. Majda-Stanislawska E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr Infect Dis J 2004; 23: 571-4.
60. Dentico P, Ciavarella N, Scaraggi FA et al. Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients. Haemophilia 1996; 2: 37-40.
61. Hess G, Clemens R, Bienzle U, Schonfeld C, Schunck B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995; 46: 40-2.
62. Joines RW, Blatter M, Abraham B et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001; 19: 4710-9.
63. Diaz-Mitoma F, Law B, Parsons J. A combined vaccine against hepatitis A and B in children and adolescents. Pediatr Infect Dis J 1999; 18: 109-14.
64. Van Damme P. Long-term protection after hepatitis A and B vaccination: an update. Acta Gastroenterol Belg 2003; 66: 247-9.